In this video, Raj Chovatiya, MD, PhD, discusses the latest findings on the use of topical roflumilast in patients with ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

The programme comprises two Phase III trials, ONWARD1 and ONWARD2, and an optional long-term extension trial, ONWARD3.

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

Abdominal fat is tied to psoriasis risk much more strongly than fat located elsewhere on the body Originally published on ...